Amylin Pharmaceuticals to Present at Morgan Stanley Global Healthcare Unplugged Conference
September 03 2009 - 4:15PM
PR Newswire (US)
SAN DIEGO, Sept. 3 /PRNewswire-FirstCall/ -- Amylin
Pharmaceuticals, Inc. (NASDAQ:AMLN) will be presenting at the
Morgan Stanley Global Healthcare Unplugged Conference on Monday,
September 14, 2009 at 9:10 a.m. ET / 6:10 a.m. PT in New York.
Daniel M. Bradbury, president and chief executive officer of Amylin
Pharmaceuticals, will provide a corporate overview. The live
presentation will be webcast, and a recording will be made
available following the event. The webcast and recording will be
accessible through Amylin's corporate Web site, located at
http://www.amylin.com/. To access the live webcast, please log on
to Amylin's site approximately fifteen minutes prior to the
presentation to register and download any necessary audio software.
About Amylin Pharmaceuticals Amylin Pharmaceuticals is a
biopharmaceutical company committed to improving lives through the
discovery, development and commercialization of innovative
medicines. Amylin has developed and gained approval for two
first-in-class medicines for diabetes, SYMLIN (pramlintide acetate)
injection and BYETTA (exenatide) injection. Amylin's research and
development activities leverage the Company's expertise in
metabolism to develop potential therapies to treat diabetes and
obesity. Amylin is headquartered in San Diego, California. Further
information about Amylin Pharmaceuticals is available at
http://www.amylin.com/. DATASOURCE: Amylin Pharmaceuticals, Inc.
CONTACT: Michael York, Senior Director, Investor Relations of
Amylin Pharmaceuticals, Inc., +1-858-552-2200, ext. 8602 Web Site:
http://www.amylin.com/
Copyright
Amylin Pharmaceuticals, Inc. (MM) (NASDAQ:AMLN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Amylin Pharmaceuticals, Inc. (MM) (NASDAQ:AMLN)
Historical Stock Chart
From Jul 2023 to Jul 2024